Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
about
Follicular lymphoma: 2012 update on diagnosis and managementUpdate on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphomaFollicular lymphoma: 2011 update on diagnosis and managementRole of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphomaFollicular lymphoma: 2014 update on diagnosis and managementRadioimmunotherapy of human tumoursImproving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.Cancer radioimmunotherapy.Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment resultsLong term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.Advances in the treatment of hematologic malignancies using immunoconjugatesBiology and treatment of follicular lymphoma.Review of Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin's lymphoma.Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?Radionuclide therapy beyond radioiodine.The role of monoclonal antibodies in the treatment of lymphomas.Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.Novel antibody-based proteins for cancer immunotherapy.Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.Advances and application of radioimmunotherapy in non-Hodgkin lymphoma.Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.Whither Radioimmunotherapy: To Be or Not To Be?Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective
P2860
Q22252956-12E651E6-B88A-4908-890B-64C4D8942FB9Q24633710-2A48E0CB-E18E-450E-966F-C624D1F20B7EQ26851450-F4821AF9-0FCE-449C-A5F4-D9FA585E98BEQ27000310-FA8427C2-F451-46CC-B749-00493B628928Q27021850-FEA11EA3-A6AF-4DBE-9D3F-6D1B2DD97E01Q28088825-C24597DE-D04E-4781-94B2-265E43D289BFQ33645793-7DAEEC11-06DA-4496-9054-6F160B41F7BEQ35070045-6E9CAC3C-1E98-4ECB-A8B1-D5CBDCDC965FQ35186372-957824A0-250F-4FDA-BBF1-01442710D131Q35534203-51CAF9D9-28C7-4BFA-810C-3A4302B51F09Q35786490-FADE53B0-74F0-4A9D-8AF8-BF00DE6C0FA1Q37045536-1202F9C9-F434-4F0A-AF65-F1F7C9B91964Q37169112-8B57DB05-9768-45C2-8AD2-7A38F428F212Q37697843-9CAFF59C-AB6F-43D3-A01C-D5FC248F4CCCQ37810118-533EAA6F-31A8-4840-8BCB-77C562848CC6Q37824258-093B1B52-B7F0-4CDC-974D-5B83656FF895Q37877728-C578BF29-C1BD-40B5-94D1-4A4BB077E522Q37930456-5D73D291-314C-4805-AD73-8E165B25309CQ38027798-1E353F89-2231-44E7-8092-6C55C9B92438Q38069595-829215B9-A4BC-4749-88A6-82DEA395827DQ38088002-CA8DFE3D-9CA2-4665-9165-4B38F2912E8DQ38161370-920BB4D3-1AEC-412F-92FC-1C743766F203Q38396244-3FBDCB9E-098B-4082-A67C-0DB9A8E59C8FQ38473731-50BC9875-7B7B-419C-B01C-DC05451962EFQ38594531-EB39D968-B0A2-445A-B420-DA9FC7070291Q39386942-6FF28D4A-8FB1-4CA0-A35E-9AA17C806ACEQ39591787-F085FB8E-A752-43F9-8315-F093769ECE76Q48201625-6F2DAC25-AAAE-456E-8711-540EDC2AA0B4Q50203410-E0FBD098-9A72-4B32-9470-F5605E703383Q51076576-7C435621-77E0-4E7B-809D-6ACE958B6F9D
P2860
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Fludarabine and mitoxantrone f ...... non-randomised trial (FLUMIZ).
@en
Fludarabine and mitoxantrone f ...... phase II non-randomised trial
@nl
type
label
Fludarabine and mitoxantrone f ...... non-randomised trial (FLUMIZ).
@en
Fludarabine and mitoxantrone f ...... phase II non-randomised trial
@nl
prefLabel
Fludarabine and mitoxantrone f ...... non-randomised trial (FLUMIZ).
@en
Fludarabine and mitoxantrone f ...... phase II non-randomised trial
@nl
P2093
P50
P1433
P1476
Fludarabine and mitoxantrone f ...... non-randomised trial (FLUMIZ).
@en
P2093
Alessandro Pulsoni
Alessio Perotti
Alfonso Zaccaria
Amalia De Renzo
Cinzia Pellegrini
Enrica Marchi
Luciano Guardigni
Luigi Rigacci
Marco Gobbi
Maria Giuseppina Cabras
P304
P356
10.1016/S1470-2045(08)70039-1
P577
2008-03-14T00:00:00Z